GHK-Cu
Skin Health & Anti-AgingResearch-GradeLast reviewed: September 20, 2026
Quick Facts
- What it is
- A naturally occurring copper-binding peptide studied for skin, hair, and connective-tissue repair — reviews by its discoverer report thousands of genes with shifted expression in cell-line data.
- How it's taken
- Topical (creams/serums) or subcutaneous injection
- Half-life
- Short plasma half-life; effects persist via gene-expression changes
- Typical research dose
- Topical 1–3%; injectable 1–2 mg/day in 30-day cycles
- Research status
- Topical permitted in cosmetics; injectable not FDA-approved — research use only.
On this page
- 1.Where to source GHK-Cu
- 2.What is GHK-Cu?
- 3.How does GHK-Cu work?
- 4.What is GHK-Cu used for?
- 5.How long does GHK-Cu take to work?
- 6.How is GHK-Cu dosed?
- 7.How is GHK-Cu administered?
- 8.What does GHK-Cu stack well with?
- 9.What are the side effects of GHK-Cu?
- 10.Does GHK-Cu interact with other drugs?
- 11.How should GHK-Cu be stored?
- 12.What are the limitations of GHK-Cu research?
- 13.GHK-Cu FAQ
- 14.References
- 15.Published Studies
Where to source GHK-Cu
Topical GHK-Cu is widely available in cosmetic skincare products at 1–3% concentrations. Injectable research-grade GHK-Cu is sold by specialty peptide vendors; the FDA's 2023 Category-2 safety-risk listing for compounded injectable GHK-Cu has since been withdrawn per the agency's own list (fda.gov, current as of April 2026), though it remains off the 503A Bulks List as well. The vendors highlighted below have been vetted for transparent third-party testing, traceable batch documentation, and verified discount codes — including an EU shipping option for international research.
ILS Laboratories · batch COAs
Kovera, Chromate and BioRegen · certificates checked at each lab
Batch-traceable COAs · cold-chain shipping
Your Discount Code
See offer (opens Midwest Peptide in a new tab)Also stocking GHK-Cu
Royal Peptides, Vital Core Research, Vortex Research, Aero Peptides — each carries a current price row for this compound.
What is GHK-Cu?
GHK-Cu — also known as copper tripeptide-1, GHK copper peptide, or simply GHK — is a naturally occurring copper-binding tripeptide (glycyl-L-histidyl-L-lysine) first isolated by Loren Pickart in 1973 from human plasma albumin. It exists naturally in plasma, saliva, and urine — at age 20 plasma levels average ~200 ng/mL, declining to ~80 ng/mL by age 60. This decline coincides with reduced regenerative capacity. Reviews by Pickart and colleagues report, from Broad Institute Connectivity Map data in cancer cell lines, that GHK shifts expression of over 4,000 human genes, including genes for collagen synthesis, wound healing, anti-inflammatory signaling, and tissue remodeling. Often paired with BPC-157 + TB-500 in the GLOW blend for skin and recovery, or in the broader KLOW blend. New to peptide research? Start with the basics
Reported benefits:
- Stimulates collagen and glycosaminoglycan synthesis in skin fibroblasts
- Reviews by its discoverer report over 4,000 human genes with shifted expression (database analysis of cancer cell lines)
- Wound healing: in one rat study, a topical copper-tripeptide gel reduced ischemic wound area by 64.5% at day 13, versus 45.6% with vehicle gel and 28.2% untreated
- Hair: no study comparing GHK-Cu with minoxidil was found; the one human hair series tested a multi-ingredient injection
- Anti-inflammatory and antioxidant activity
- Available topically (cosmetic skincare) and as injectable research peptide
Common research dose: Topical: 1–3% concentration in serums/creams, applied 1–2× daily. Injectable research protocol: 1–2 mg subcutaneously, 30-day cycle (typically 1 mg days 1–15, escalating to 2 mg days 16–30), then 30-day break.
Where to buy: PP maintains a vetted list of peptide vendors with verified discount codes. See Verified Discount Codes for current options.
How does GHK-Cu work?
GHK-Cu shuttles copper into cells where it powers enzymes including lysyl oxidase (collagen crosslinking), superoxide dismutase (antioxidant defense), and cytochrome c oxidase (cellular energy). A review by Pickart and Margolina reports, from Broad Institute Connectivity Map data in cancer cell lines, that GHK shifts expression of over 4,000 human genes, including genes for collagen synthesis, tissue remodeling, and anti-inflammatory signaling. That gene figure comes from a database analysis, not from a primary experiment in human tissue.
- Copper Shuttle [1]. GHK-Cu carries copper into cells where it powers enzymes including lysyl oxidase (collagen crosslinking), superoxide dismutase (antioxidant defense), and cytochrome c oxidase (cellular energy). The copper-binding capability is what gives GHK-Cu its name and broad mechanistic reach.
- Gene Expression Modulation [2]. A review by Pickart and Margolina reports, from Connectivity Map data in cancer cell lines, that GHK shifts expression of over 4,000 human genes. Studies report higher type I and III collagen and glycosaminoglycan production. In cultured rat dermal fibroblasts, decorin mRNA reached 302% of control levels (3.02×) with GHK-Cu (Siméon 2000, PMID 11121126). The reviews also describe downregulation of inflammatory and senescence pathways.
- Collagen Synthesis [3][4]. Stimulates collagen synthesis at picomolar to nanomolar concentrations in skin fibroblasts. Notably stimulates BOTH collagen production AND breakdown of damaged collagen via matrix metalloproteinases — true tissue remodeling, not just deposition.
- Hair Follicle Size. A 2008 review by Pickart (PMID 18644225) reports that GHK-Cu increases hair follicle size. No primary study was found showing that GHK-Cu activates Wnt signaling in dermal papilla cells or blocks follicle miniaturization; the one dermal-papilla study found tested a different copper peptide, AHK-Cu (Pyo 2007, PMID 17703734).
- Anti-Inflammatory & Antioxidant [5]. Reduces TNF-alpha and IL-6 in dermal fibroblasts. Stimulates antioxidant enzymes including superoxide dismutase. Reduces oxidative stress markers in cellular and animal studies.
What is GHK-Cu used for?
GHK-Cu's research evidence base is one of the broadest of any peptide — decades of cell, animal, and human studies across wound healing, skin rejuvenation, hair growth, anti-aging gene expression, and systemic healing applications. Pickart and Margolina's reviews describe GHK as "resetting DNA to a healthier state", based on Connectivity Map cell-line data showing over 4,000 genes with shifted expression.
- Wound Healing [6]. In a study of 24 rats with 6-mm wounds in an ischemic skin flap, a topical tripeptide-copper gel (Iamin 2%) reduced wound area by 64.5% at day 13, versus 45.6% with the vehicle gel alone and 28.2% with no treatment; the gel differed significantly from its vehicle only on days 3 and 9 (Canapp 2003, PMID 14648529). This was a topical product, not injected GHK-Cu. Effects observed in dermal, corneal, and surgical wound models.
- Skin Rejuvenation [7]. Pilot studies on aged skin show increased thickness, elasticity, hydration, and collagen density. Comparable to tretinoin in some endpoints, with cleaner tolerability profile.
- Hair Growth. No head-to-head or placebo-controlled study comparing GHK-Cu with minoxidil was found. One open-label, single-arm series (Kapoor 2018, 1,000 patients) used scalp injections of a multi-ingredient formulation that included copper tripeptide-1; the effect of GHK-Cu alone cannot be separated. Topical formulations are widely marketed for hair regrowth.
- Anti-Aging Gene Expression [2]. Pickart and Margolina's reviews describe "resetting DNA to a healthier state", based on Connectivity Map data in cancer cell lines showing over 4,000 genes with shifted expression. This is a database analysis by the compound's discoverer, not a primary human study.
- Systemic Healing. Animal studies show systemic effect: GHK-Cu injected in one tissue area improves healing at distant sites (rats, mice, pigs). This systemic activity is part of the rationale for injectable use over topical-only application.
How long does GHK-Cu take to work?
GHK-Cu effects develop on multiple timescales depending on route. Topical: visible skin texture changes typically 4–8 weeks of consistent use. Injectable: skin improvements within the first 30-day cycle; hair changes typically 60–90 days (second cycle). Systemic effects (gene expression modulation) are measurable within hours of dosing but cumulative over cycles. Most users complete 3 injectable cycles before assessing full results.
Topical: visible skin texture changes typically 4–8 weeks of consistent use. Injectable: skin improvements within the first 30-day cycle; hair changes typically 60–90 days (second cycle). Systemic effects (gene expression modulation) are measurable within hours of dosing but cumulative over cycles. Most users complete 3 injectable cycles before assessing full results — consistent with the gene-expression-driven mechanism where effects accumulate via tissue remodeling rather than acute pharmacology.
How is GHK-Cu dosed?
No human study of injected GHK-Cu was found — every study located for this page tested it topically. The figures below separate what those topical studies actually applied from the injectable figures, which are reported here strictly as community-reported practice, not trial-derived.
Prof. Peptide reports what trials established and what research communities practice, labelled separately. Neither is a recommendation.
Need to calculate a dose?
Use the Prof. Peptide dosage calculator for accurate reconstitution and dosing math.
Open CalculatorWhat the cited literature administered (topical only)
Badenhorst et al. 2016 (Human RCT — randomized, double-blind, split-face trial, though published in a journal not indexed in PubMed/MEDLINE) applied a 0.1%-equivalent nano-lipid-carrier GHK-Cu serum to the faces of 40 women (ages 40–65) once daily for 8 weeks, reporting a 31.6% reduction in wrinkle volume versus a commercial Matrixyl 3000 comparator and a 55.8% reduction versus a vehicle-only control. A currently recruiting Phase 2 trial (NCT07437586, N=60 planned) is applying a 0.1% w/w GHK-Cu gel once daily for 14 days to standardized wounds, but has not yet posted results. Two other frequently cited topical studies (Leyden et al., facial and eye cream, presented at the American Academy of Dermatology's 2002 meeting) were never published as peer-reviewed papers and have no PMID to verify.
Community-reported practice (unverified)
- Topical (cosmetic). 1–3% concentration in serums or creams, applied 1–2× daily — a higher concentration than either the recruiting wound trial's 0.1% w/w gel or Badenhorst 2016's serum.
- Injectable Phase 1 (Days 1–15). 1 mg/day subcutaneously before bed — no human study of injected GHK-Cu was found to source this from.
- Injectable Phase 2 (Days 16–30). 2 mg/day subcutaneously.
- Cycle structure. 30 days on, 30 days off. Some users report completing 3 cycles before assessing results.
- Reconstitution. 50 mg vial + 10 mL bacteriostatic water = 5 mg/mL (20 units = 1 mg). See How is GHK-Cu administered? for the full reconstitution table.
Topical use has the evidence base described above and is FDA-permitted. Injectable use is reported here only as community practice, has no human study behind it, and is subject to the FDA's 2023 restriction on compounded injectable GHK-Cu preparation.
The Prof. Peptide dosage calculator converts between milligram figures and syringe units for a given reconstitution; it performs the arithmetic and does not set a schedule. The GHK-Cu reconstitution calculator works the same arithmetic against the vial sizes tracked for this compound.
How is GHK-Cu administered?
GHK-Cu is administered topically (cosmetic skincare — FDA-permitted) or by subcutaneous injection (not FDA-approved; the FDA's 2023 Category-2 safety-risk listing for the injectable route has since been withdrawn per the agency's own list, though injectable GHK-Cu is also not on the 503A Bulks List). Topical use is the more defensible starting point and has the strongest evidence base. Injectable produces systemic effects across tissues but requires research-grade material and carries regulatory restrictions. For the practical mechanics of insulin syringes for the injectable route, see the syringes and injection technique guide.
- Topical. Applied to clean dry skin, twice daily. Formulation guidance keeps raw vitamin C out of the same product, citing copper–vitamin C interactions that destabilize both ingredients.
- Injectable route. Subcutaneous injection at bedtime, at least 2 hours after last meal. Common sites: abdomen, thigh, upper arm.
- Time of day. Bedtime preferred (aligns with natural overnight tissue-repair pulses).
- With or without food. An empty stomach is preferred for injectable (2+ hours after eating).
- Site rotation. Reported practice alternates abdomen, thigh, and upper arm for injectable.
- Reconstitution handling. Bacteriostatic water, swirl gently, never shake. Light-sensitive — store in opaque container.
- Direct sunlight is kept off the site. Reported practice keeps direct sunlight off injection sites for 24–48 hours afterwards.
Timing context. GHK-Cu's effects accumulate via gene expression and tissue remodeling rather than acute pharmacology — the per-dose plasma profile matters less than cycle consistency. Topical and injectable produce different effect profiles: topical drives localized skin effects through direct dermal exposure; injectable produces systemic gene-expression modulation across tissues. Many users combine both routes (topical for skin, injectable for systemic) during research cycles.
| Aspect | Reported |
|---|---|
| Frequency | Topical: 1–2× daily. Injectable: once daily; a 30-day cycle, 3 cycles typical, is reported community practice, not derived from a trial or label; Prof. Peptide has not independently verified it. |
| Best time of day | Topical: AM or PM. Injectable: bedtime preferred. |
| Food | Injectable: empty stomach preferred (2+ hours after eating) |
| Route choice | Topical for skin-focused (safer, FDA-permitted); injectable for systemic effects (not FDA-approved; off both the Category 2 risk list and the 503A Bulks List) |
| Half-life | Short plasma half-life; biological effects persist via gene-expression changes |
| Steady-state | Tissue effects accumulate over cycles — 3-cycle pattern is standard before full assessment |
Reconstitution math. Water volume sets concentration: a lower volume yields a higher concentration and a smaller syringe draw for a given mg amount, and the reverse for a higher volume. GHK-Cu research vials are typically 50 mg — significantly larger than other research peptides. Because the per-dose amount is small (1–3 mg), higher reconstitution volumes (5–10 mL) are used to keep syringe draws practical. All units below are measured on a U-100 insulin syringe (100 units = 1 mL). The table assumes a 50 mg vial.
| BAC water | Concentration | 1 mg dose | 2 mg dose | 3 mg dose | 5 mg dose |
|---|---|---|---|---|---|
| 2 mL | 25 mg/mL | 4 units | 8 units | 12 units | 20 units |
| 5 mL | 10 mg/mL | 10 units | 20 units | 30 units | 50 units |
| 10 mL | 5 mg/mL | 20 units | 40 units | 60 units | 100 units |
Units vs mcg. At a 50 mg vial, each unit drawn delivers 250 mcg of GHK-Cu at 2 mL reconstitution, 100 mcg at 5 mL, and 50 mcg at 10 mL — the reconstitution volume determines the mcg-per-unit conversion. For a primer on reading insulin syringes and choosing the right barrel size, see our guide on syringes and injection technique.
Common question: How does topical GHK-Cu compare with injections?
What does GHK-Cu stack well with?
GHK-Cu's canonical pairing is with BPC-157 + TB-500 in the GLOW blend for skin/recovery synergy, or in the KLOW blend (adds KPV). Topical retinoids combine well (collagen synthesis + cell turnover), and topical niacinamide is compatible. The most important non-stacking is vitamin C: topical high-concentration vitamin C destabilizes the copper complex, so apply at different times of day.
- BPC-157 + TB-500 (GLOW Stack). BPC-157 + TB-500 combined with GHK-Cu in the GLOW blend for skin/recovery synergy. KPV adds anti-inflammatory effect for the broader KLOW blend.
- Topical retinoids. Combination of GHK-Cu (collagen synthesis) + retinoid (cell turnover) is well-tolerated and synergistic.
- Vitamin C serum. Reported applied at separate times (AM vitamin C, PM GHK-Cu) to avoid copper-vitamin C neutralization.
- Topical niacinamide. Compatible — both support barrier function.
- Conflicts: high-dose oral copper supplements. During injectable GHK-Cu cycles — theoretical risk of total copper overload.
What are the side effects of GHK-Cu?
GHK-Cu is NOT FDA-approved for injectable use. The FDA's 2023 Category-2 safety-risk listing for compounded injectable GHK-Cu has since been withdrawn per the agency's own list (fda.gov, current as of April 2026); injectable GHK-Cu is also absent from the 503A Bulks List. Topical GHK-Cu is widely available in cosmetic formulations. The most common practical issue is topical irritation — typically resolves with reduced concentration or frequency. Mild injection-site reactions are reported for injectable use. Copper allergy is a real but uncommon contraindication.
Common (most users)
- Mild injection site reactions. Injectable route only.
- Possible scalp or skin irritation. Topical route.
- “Copper uglies”. Transient skin purging in first 1–2 weeks (rare); self-resolving.
Less common (moderate)
- Mild headache. Uncommon.
- Mild fatigue. Uncommon.
- Allergic reactions. In copper-sensitive individuals.
Serious (rare)
- Copper allergy reactions. Hives, swelling, breathing issues — discontinue immediately.
- Theoretical copper toxicity. Negligible at standard doses but possible with chronic high-dose use.
- Long-term injectable safety. Not formally established.
GHK-Cu is NOT FDA-approved for injectable use. The FDA's 2023 Category-2 safety-risk listing for compounded injectable GHK-Cu has since been withdrawn per the agency's own list (fda.gov, current as of April 2026); injectable GHK-Cu remains off the 503A Bulks List as well. Topical GHK-Cu is widely available in cosmetic formulations. The most common practical issue is topical irritation — typically resolves with reduced concentration or frequency.
Does GHK-Cu interact with other drugs?
GHK-Cu's most relevant interactions are with vitamin C (high-concentration topical destabilizes the copper complex — apply at different times), topical hydroquinone (limited data on combination), and copper-binding drugs like D-penicillamine or chelation therapy (theoretical interaction with injectable use). No significant systemic drug interactions documented at standard cosmetic doses.
- Vitamin C (high concentration topical). Destabilizes copper complex; apply at different times.
- Topical hydroquinone. Limited data on combination.
- No significant systemic drug interactions documented at standard cosmetic doses.
- Injectable: theoretical interaction with chelation therapy or D-penicillamine (copper-binding drugs).
How should GHK-Cu be stored?
- Lyophilized: -20°C long-term, 2–8°C short-term.
- Topical formulations: room temperature in opaque packaging (light-sensitive).
- Reconstituted injectable: 2–8°C, refrigerated, is standard practice once dissolved. Prof. Peptide has not identified a manufacturer label, published study, or lab document establishing how long reconstituted research-grade GHK-Cu remains stable — this page does not state a duration as fact.
- Formulations are reported to keep it apart from pure vitamin C.
- Reconstitution uses bacteriostatic water for injection. Swirl gently — do not shake.
- A solution that is cloudy, discolored, or contains particles is discarded.
What are the limitations of GHK-Cu research?
GHK-Cu has one of the strongest evidence bases of any peptide on Prof. Peptide — decades of cell, animal, and human studies with consistent results across research groups. Topical use is established in cosmetic formulations and widely available without prescription. Injectable use is NOT FDA-approved; the FDA's 2023 Category-2 safety-risk listing for compounded injectable GHK-Cu has since been withdrawn per the agency's own list (fda.gov, current as of April 2026), and injectable GHK-Cu is also absent from the 503A Bulks List. Long-term injectable safety data is not established. NOT currently on the WADA prohibited list.
GHK-Cu has one of the strongest evidence bases of any peptide on Prof. Peptide — decades of cell, animal, and human studies, with consistent results across research groups.
Topical GHK-Cu is established in cosmetic formulations and widely available without prescription. Injectable GHK-Cu is NOT FDA-approved. The FDA placed compounded injectable GHK-Cu in Category 2 of its bulk-drug-substance safety-risk list in 2023; the agency's own list (fda.gov, current as of April 2026) now shows that nomination withdrawn, so injectable GHK-Cu is no longer flagged there. That withdrawal does not place it on the 503A Bulks List, which FDA's own list of that name does not mention GHK-Cu on at all, so its compounding is not affirmatively authorized on that separate ground.
Most clinical evidence is for topical applications; systemic effects from injection are derived from animal studies and limited human research. Long-term injectable safety data is not established.
Anti-doping: GHK-Cu is NOT currently on the WADA prohibited list. Research-grade material is sold for laboratory use only.
GHK-Cu FAQ
Is GHK-Cu FDA-approved?
Topical GHK-Cu is widely available in cosmetic formulations without prescription. Injectable GHK-Cu is NOT FDA-approved. The FDA placed compounded injectable GHK-Cu in Category 2 of its bulk-drug-substance safety-risk list in 2023, citing limited human safety data; the agency's own list (fda.gov, current as of April 2026) now shows that nomination withdrawn, and injectable GHK-Cu is also absent from the 503A Bulks List, so its compounding is not affirmatively authorized on that separate ground. Most clinical evidence supports topical use; systemic effects from injection are derived from animal studies and limited human research.
How is GHK-Cu different from BPC-157?
Different mechanisms. GHK-Cu is a copper-binding tripeptide studied for collagen synthesis, tissue remodeling, and anti-inflammatory signaling — primarily through copper-shuttling. Reviews by Pickart and colleagues report, from Broad Institute Connectivity Map data in cancer cell lines, that GHK shifts expression of over 4,000 human genes. BPC-157 is a 15-amino-acid peptide that drives angiogenesis (VEGF/eNOS) and tissue repair through nitric oxide and FAK-paxillin pathways. They are commonly stacked together (often in the GLOW blend) because their mechanisms are complementary, not redundant. See the BPC-157 vs GHK-Cu comparison for a side-by-side breakdown.
Topical vs injectable — which is better?
Topical has the strongest evidence base, the longest history of safe use, and is FDA-permitted in cosmetic formulations. Injectable produces systemic effects (gene expression modulation across tissues) but is not FDA-approved and has stricter regulatory restrictions. For skin-focused applications, topical is the more defensible choice. For broader regenerative effects (hair + skin + tissue), injectable is what's used in functional medicine settings — at the user's risk regarding regulatory and quality issues.
Does GHK-Cu work for hair loss?
No head-to-head or placebo-controlled study comparing GHK-Cu with minoxidil was found. The human hair data is one open-label, single-arm series (Kapoor 2018, 1,000 patients) of scalp injections of a multi-ingredient formulation that included copper tripeptide-1, so the effect of GHK-Cu alone cannot be separated. Community reports describe visible hair changes at 60–90 days. Topical GHK-Cu products marketed for hair are widely available.
What are "copper uglies"?
Slang for transient skin purging — increased breakouts or skin reactivity in the first 1–2 weeks of GHK-Cu use as the peptide accelerates skin cell turnover. Uncommon and self-resolving. If skin irritation persists beyond 2 weeks, discontinue and assess for copper sensitivity.
Can I combine GHK-Cu with retinoids or vitamin C?
Retinoids — yes, generally well-tolerated. The combination of GHK-Cu (collagen synthesis) + retinoid (cell turnover) is a common synergistic skincare protocol. Vitamin C — apply at separate times (AM vitamin C, PM GHK-Cu). High-concentration topical vitamin C destabilizes the copper complex; both ingredients lose efficacy when applied simultaneously.
How long until I see results?
Topical: visible skin texture changes typically 4–8 weeks. Injectable: skin improvements within first 30-day cycle. Hair changes typically 60–90 days (second cycle). Systemic gene expression effects are measurable within hours of dosing but cumulative over cycles.
Where can I buy GHK-Cu?
Topical GHK-Cu is widely available in cosmetic skincare products at 1–3% concentrations. Injectable research-grade GHK-Cu is sold by specialty peptide vendors; the FDA's 2023 Category-2 safety-risk listing for compounded injectable GHK-Cu has since been withdrawn per the agency's own list (fda.gov, current as of April 2026), though it remains off the 503A Bulks List as well. PP maintains a list of vetted vendors with verified discount codes — see Verified Discount Codes .
References
- Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci. 2018;19(7):1987. https://pmc.ncbi.nlm.nih.gov/articles/PMC6073405/
- Pickart L, Vasquez-Soltero JM, Margolina A. GHK and DNA: Resetting the Human Genome to Health. Biomed Res Int. 2014;2014:151479.
- Pickart L, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. Biomed Res Int. 2015;2015:648108. https://pmc.ncbi.nlm.nih.gov/articles/PMC4508379/
- Maquart FX, Pickart L, et al. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Letters. 1988.
- Wikipedia. Copper peptide GHK-Cu. https://en.wikipedia.org/wiki/Copper_peptide_GHK-Cu
- Innerbody Research. GHK-Cu Peptide. https://www.innerbody.com/ghk-cu-peptide
- Pickart L. The Human Tripeptide GHK-Cu in Prevention of Oxidative Stress and Degenerative Conditions of Aging. Oxid Med Cell Longev. 2012.
- Badenhorst T, Svirskis D, Merrilees M, Bolke L, Wu Z. Effects of GHK-Cu on MMP and TIMP Expression, Collagen and Elastin Production, and Facial Wrinkle Parameters. J Aging Sci. 2016;4:166. DOI 10.4172/2329-8847.1000166. https://doi.org/10.4172/2329-8847.1000166
- Topical GHK-Cu Gel for Acute Skin Wound Healing, NCT07437586. https://clinicaltrials.gov/study/NCT07437586
Published Studies
Plain-English summaries of the peer-reviewed studies behind the claims above. Click any title to read the source paper.
Pickart L, Vasquez-Soltero JM, Margolina A
The comprehensive review that established GHK-Cu as a multi-pathway skin regeneration agent. The paper documents that GHK-Cu — first isolated by Pickart in 1973 when he discovered it made aged liver tissue behave like younger tissue — accelerates wound healing, improves transplanted skin take, stimulates collagen and glycosaminoglycan synthesis, attracts immune and endothelial cells to injury sites, and restores replicative vitality to fibroblasts after radiation therapy. Crucially, plasma GHK levels decline from 200 ng/mL at age 20 to 80 ng/mL by age 60.
Pickart L, Margolina A
A landmark review synthesizing GHK-Cu's known biological actions with groundbreaking gene expression data from the Broad Institute's Connectivity Map. Using this publicly available genomic database, researchers found that GHK-Cu modulates expression of genes across an extraordinary range of categories — wound healing, collagen synthesis, anti-inflammatory signaling, nerve growth, antioxidant defense, and DNA repair.
Pickart L, Margolina A
A focused review of GHK-Cu's applications in skin protection and cancer prevention — two applications that emerge from the same underlying mechanism of DNA repair and gene expression modulation. The paper documents how GHK-Cu's ability to modulate 84 genes associated with DNA repair and cancer suppression could make it relevant for skin cancer prevention alongside its established role in skin regeneration and anti-aging.
Adnan SB, Maarof M, Fauzi MB, et al.
The most current systematic review of GHK-Cu in wound healing, covering studies published between 2016 and 2025. The paper documents GHK-Cu's role across all phases of wound repair — stimulating fibroblast migration, enhancing collagen deposition, supporting angiogenesis, and facilitating extracellular matrix remodeling. It also covers advanced formulations including nanoparticle conjugates and hydrogels.
Leyden JJ, et al.
One of the few controlled human clinical trials of GHK-Cu — examining its use after CO2 laser skin resurfacing in 13 patients. Patient satisfaction was significantly higher in the GHK-Cu group (p=.04), and data suggested superior improvement in wrinkle scores in Fitzpatrick classes II and III.
Related Peptides
Related Blends
Comparisons
We may earn commissions from peptide vendor affiliate links.
Have a question about GHK-Cu? Send us an email